手法を比較
選択した手法を並べて確認できます。異なる行はハイライト表示されます。
| リスク調整済み第IV相試験× | 逆確率重み付け法 (IPW / IPTW)× | |
|---|---|---|
| 分野≠ | 疫学 | 因果推論 |
| 系統≠ | Process / pipeline | Regression model |
| 提唱年≠ | 1990s–2000s (formalized with ICH E2E and EMA PASS guidelines) | 2000 |
| 提唱者≠ | Regulatory and pharmacoepidemiology community (ICH, EMA, FDA frameworks) | Robins, Hernán & Brumback |
| 種類≠ | Observational / quasi-experimental clinical study design | Causal inference weighting estimator |
| 原典≠ | Strom, B. L. (Ed.). (2005). Pharmacoepidemiology (4th ed.). John Wiley & Sons. ISBN: 978-0470863107 | Robins, J. M., Hernán, M. A., & Brumback, B. (2000). Marginal Structural Models and Causal Inference in Epidemiology. Epidemiology, 11(5), 550-560. DOI ↗ |
| 別名≠ | risk-adjusted post-marketing surveillance study, adjusted Phase IV trial, risk-stratified post-authorization study, PASS with risk adjustment | IPW, IPTW, inverse probability of treatment weighting, marginal structural model weighting |
| 関連≠ | 3 | 5 |
| 概要≠ | A risk-adjusted Phase IV study is an observational or semi-experimental post-marketing study conducted after a drug or device has received regulatory approval. It uses statistical risk-adjustment techniques — such as propensity score matching, inverse probability weighting, or multivariable regression — to control for confounding by indication and baseline patient differences, thereby producing more credible safety, effectiveness, and utilization estimates than unadjusted real-world analyses. | Inverse Probability Weighting is a causal-inference method that assigns each observation a weight equal to the inverse of its probability of receiving the treatment it actually received. Introduced by Robins, Hernán and Brumback (2000) for marginal structural models, it builds a pseudo-population in which treatment is independent of measured confounders, balancing selection bias. |
| ScholarGateデータセット ↗ |
|
|